Conclusions The exposure of IDeg at steady state during
once-daily dosing was similar in younger adult and elderly
subjects. The glucose-lowering effect of IDeg was
numerically lower in elderly subjects compared with
younger adults, but no significant differences wereobserved between age groups. The ultra-long pharmacokinetic
and pharmacodynamic properties of IDeg observed
in younger adults were preserved in elderly subjects with
type 1 diabetes.
Clinical trials.gov number: NCT00964418